Ongoing Clinical Trials Actively Recruiting Adolescent and Young Adult Survivors of Childhood Cancer

Study Type: Randomized/interventional

Study Title: A Randomized Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer

Study Sponsor and Collaborators: St. Jude Children’s Research Hospital

Purpose: Five-year survival following a diagnosis of childhood cancer has reached 83%, making long-term health outcomes among survivors an important concern. The researchers at St. Jude Children’s Research Hospital want to determine if a rewards-based physical activity intervention delivered via an interactive website among young adolescent childhood cancer survivors, ages 11–14, will increase physical activity levels and improve cardiovascular and musculoskeletal health.

Ages Eligible for Study: 11 to 14 years

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Change in daily average of moderate and vigorous physical activity levels between groups (time frame: baseline, week 12, and week 24)

Principal Investigator: Kirsten K. Ness, PT, PhD, St. Jude Children’s Research Hospital; 866-278-5833, info@stjude.org

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01778127

Study Title: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial

Study Sponsor and Collaborators: City of Hope Medical Center, National Cancer Institute

Purpose: To study the side effects and how well low-dose carvedilol works in preventing congestive heart failure in younger cancer survivors exposed to high-dose anthracyclines for management of childhood cancer

Ages Eligible for Study: 16 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Left-ventricular (LV) thickness-dimension ratio, reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole (time frame: up to 24 months)

Principal Investigator: Saro H. Armenian, DO, MPH, City of Hope Medical Center; 626-471-7320, sarmenian@coh.org

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01347970

Study Title: Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer

Study Sponsor and Collaborators: Clinical and Translational Science Institute of the University of Minnesota

Purpose: Adult survivors of childhood cancer are at high risk of developing cardiovascular disease. The primary objective of this study is to evaluate the effects of 6 months of statin therapy on conduit artery endothelial function in young adult survivors of childhood cancer. The investigators hypothesize that, compared to placebo, atorvastatin will significantly increase brachial artery flow-mediated dilation in survivors of childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Ages Eligible for Study: 18 to 39 years

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Change from baseline in brachial artery flow-mediated dilation at 6 months (time frame: baseline and 6 months)

Principal Investigator: Aaron S. Kelly, PhD, Clinical and Translational Science Institute of the University of Minnesota. Contact: Cameron E. Naughton, MPA; 612-625-3623, naugh0009@umn.edu

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01733953

Study Title: A Phase II Open Label Pilot Study of the Angiotensin-Converting Enzyme Inhibitor, Perindopril, in Pediatric Cancer Survivors With Evidence of Early Cardiac Remodeling or Dysfunction

Study Sponsor and Collaborators: The Hospital for Sick Children

Purpose: To evaluate the feasibility of conducting a medical intervention trial in childhood cancer survivors with early echocardiographic evidence of cardiac remodeling

Ages Eligible for Study: Up to 20 years

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Proportion of patients consenting to the study (time frame: 18 months)

Principal Investigator: Paul Nathan, MD, Director, AfterCare Program; Staff Oncologist, The Hospital for Sick Children. Contact: Kristen George, NP, 416-813-7654, Kristen.george@sickkids.ca

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01948232

Study Title: EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center; St. Jude Children’s Research Hospital; University of Colorado, Denver; Dana-Farber Cancer Institute; University of Chicago

Purpose: To empower women to improve their health in two very important areas: breast and heart health. This 12-month study will compare two methods of informing participants about potential health risks and ways to stay healthy.

Ages Eligible for Study: 25 to 49 years

Genders Eligible for Study: Female

Accepts Health Volunteers: No

Primary Outcome Measures: Efficacy (time frame: 12 months)

Principal Investigator: Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center; 646-888-4730

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01579552

Study Title: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children’s Oncology Group

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To obtain informed consent from parents (and the child, when appropriate) of infants, children, adolescents, and young adults newly diagnosed with cancer to enter their names and certain information concerning their child into the Childhood Cancer research Network

Ages Eligible for Study: Up to 18 years

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Not available

Principal Investigator: Crystal L. Mackall, MD, National Cancer Institute; 301-402-5940, mackallc@mail.nih.gov

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01117168

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT0008274